Biohaven Therapeutics Ltd.

This study tests whether a daily pill called BHV-7000 can reduce seizures in adults with refractory focal epilepsy—a type of epilepsy that doesn't respond well to current medications. About 390 participants will receive either a low dose, a higher dose, or a placebo for 8 weeks. …

This study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not …

This study checks the long-term safety of the drug BHV-7000 in about 660 adults whose focal epilepsy has not been controlled by other treatments. Participants who completed an earlier study will continue taking the drug while doctors watch for side effects and lab changes. The go…

This study tests a new drug called taldefgrobep alfa (BHV-2000) to help adults with overweight or obesity lose weight. About 150 participants will receive either the drug or a placebo as a weekly or monthly injection for 24 weeks. The main goal is to see how much body weight chan…

This early-stage study tests whether BHV-7000 can reduce chronic pain in people with inherited erythromelalgia, a rare condition causing severe burning pain due to a genetic mutation. Only 5 adults with a specific NaV1.7 mutation will participate, comparing the drug to a placebo …